Last reviewed · How we verify

NCT02755714

Atrovent in Exercise Induced Laryngeal Obstruction (EILO)

Completed Phase 1, PHASE2 Last updated 19 August 2024
What this trial tests

Phase 1, PHASE2 trial testing Ipratropium bromide spray in Exercise Induced Laryngeal Obstruction (EILO) in 20 participants. Completed in 31 October 2020.

Timeline
22 June 2016
Primary endpoint
31 October 2020
31 October 2020

Quick facts

Lead sponsorHaukeland University Hospital
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment20
Start date22 June 2016
Primary completion31 October 2020
Estimated completion31 October 2020
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Haukeland University Hospital

Who can join

Adults 12 to 25, any sex, with Exercise Induced Laryngeal Obstruction (EILO). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exercise Induced Laryngeal Obstruction (EILO) is a condition not uncommon in otherwise healthy young people. EILO is caused by posteromedial collapse of supraglottic structures or medialization of the vocal folds, or both, during high intensity exercise. There are currently no treatments available that is properly evidence based. However, case reports suggest a possible effect from the "asthma drug" Ipratropium Bromide (Atrovent®). The current project is an open label pilot study, aiming to test if Atrovent can influence the occurence of EILO, either postponing the onset during exercise or fully prevent the condition to occur.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Exercise Induced Laryngeal Obstruction (EILO)

Currently open trials in the same condition.

Other Haukeland University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02755714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing